Suchergebnisse - "Fulvestrant/administration & dosage"
-
1
Autoren: et al.
Quelle: Future Oncol
Turner, N C, Oliveira, M, Howell, S J, Dalenc, F, Cortés, J, Gomez, H L, Hu, X, Jhaveri, K, Krivorotko, P, Loibl, S, Murillo, S M, Park, Y H, Sohn, J-H, Toi, M, Tokunaga, E, Yousef, S, Zhukova, L, Bruin, E D, Grinsted, L, Schiavon, G, Foxley, A & Rugo, H S 2024, 'A plain language summary of the CAPItello-291 study : Capivasertib in hormone receptor-positive advanced breast cancer', Future oncology (London, England), vol. 20, no. 37, pp. 2901-2913. https://doi.org/10.1080/14796694.2024.2390791Schlagwörter: Fulvestrant/administration & dosage, Receptors, Progesterone/metabolism, Receptor, ErbB-2, Clinical Studies as Topic, Receptor, ErbB-2/metabolism, Pyrimidines/therapeutic use, Breast Neoplasms, Middle Aged, Pyrimidines, Treatment Outcome, Breast Neoplasms/drug therapy, Receptors, Estrogen, Receptors, Plain Language Summary of Publication, Antineoplastic Combined Chemotherapy Protocols, Humans, ErbB-2/metabolism, Progesterone/metabolism, Female, Antineoplastic Combined Chemotherapy Protocols/therapeutic use, Estrogen/metabolism, Receptors, Estrogen/metabolism, Receptors, Progesterone, Fulvestrant, Receptor
Zugangs-URL: https://pubmed.ncbi.nlm.nih.gov/39283299
-
2
Autoren: et al.
Weitere Verfasser: et al.
Quelle: International journal of gynecological cancer
International Journal Of Gynecological CancerSchlagwörter: Ovarian Neoplasms, Adult, Fulvestrant/administration & dosage, Antineoplastic Agents, Hormonal/therapeutic use, Sex Cord-Gonadal Stromal Tumors/drug therapy, Antineoplastic Agents, Hormonal, Genital Neoplasms, Female, Genital Neoplasms, Female/drug therapy, Ovarian Neoplasms/drug therapy, Middle Aged, 3. Good health, 03 medical and health sciences, Neoplasm Recurrence, Local/drug therapy, 0302 clinical medicine, Receptors, Estrogen, Sex Cord-Gonadal Stromal Tumors, Humans, Female, Human medicine, Prospective Studies, Receptors, Estrogen/metabolism, Neoplasm Recurrence, Local, Fulvestrant, Aged
Zugangs-URL: https://pubmed.ncbi.nlm.nih.gov/40228941
https://pubmed.ncbi.nlm.nih.gov/38724237
https://hdl.handle.net/10067/2060640151162165141
https://biblio.vub.ac.be/vubir/an-openlabel-singlearm-prospective-multicenter-tandem-twostage-designed-phase-ii-study-to-evaluate-the-efficacy-of-fulvestrant -in-women-with-recurrentmetastatic-estrogen-receptorpositive-gynecological-malignancies-fuchsia-study(82bb6b14-67c9-43b4-a6dd-d8e53225ce35).html -
3
Autoren: et al.
Weitere Verfasser: et al.
Quelle: CLINICAL CANCER RESEARCH
r-FISABIO. Repositorio Institucional de Producción Científica
instname
Fundación para el Fomento de la Investigación Sanitaria y Biomédica de la Comunitat Valenciana (FISABIO)Schlagwörter: Breast Neoplasms / drug therapy, Antineoplastic Agents, Hormonal, Receptor, ErbB-2, Breast Neoplasms / chemistry, Benzimidazoles / administration & dosage, Aminopyridines, Antineoplastic Agents, Breast Neoplasms, Fulvestrant / administration & dosage, 03 medical and health sciences, 0302 clinical medicine, Humans, 10. No inequality, Fulvestrant, Neoplasm Staging, Progression-Free Survival, Aminopyridines / administration & dosage, 3. Good health, Drug Combinations, Hormonal / administration & dosage, Treatment Outcome, ErbB-2 / analysis, Breast Neoplasms / pathology, Benzimidazoles, Female, Receptor
Zugangs-URL: https://pubmed.ncbi.nlm.nih.gov/34376533
https://fundanet.fisabio.san.gva.es/publicaciones/ProdCientif/PublicacionFrw.aspx?id=12668
https://fisabio.portalinvestigacion.com/publicaciones/12668
https://clincancerres.aacrjournals.org/content/27/21/5801
https://pubmed.ncbi.nlm.nih.gov/34376533/
https://www.ncbi.nlm.nih.gov/pubmed/34376533
https://clincancerres.aacrjournals.org/content/early/2021/08/09/1078-0432.CCR-20-4685 -
4
Autoren: et al.
Weitere Verfasser: et al.
Quelle: Cancer Sci
Schlagwörter: Breast Neoplasms / blood, Aminopyridines / adverse effects, Receptor, ErbB-2, Benzimidazoles / administration & dosage, Aminopyridines, abemaciclib, Fulvestrant / administration & dosage, 0302 clinical medicine, Anastrozole / adverse effects, Aminopyridines / pharmacokinetics, East Asia, Neutropenia / chemically induced, Fulvestrant, Letrozole / administration & dosage, Aromatase Inhibitors, Benzimidazoles / pharmacokinetics, Letrozole / adverse effects, ErbB-2 / genetics, Aminopyridines / administration & dosage, metastatic, 3. Good health, Aromatase Inhibitors / administration & dosage, Treatment Outcome, Aromatase Inhibitors / adverse effects, Anastrozole / administration & dosage, Combination, Letrozole, Neutropenia / epidemiology, Drug Therapy, Combination, Female, Anastrozole / pharmacokinetics, Receptor, Benzimidazoles / adverse effects, Diarrhea, Breast Neoplasms / drug therapy, Neutropenia, Fulvestrant / adverse effects, Breast Neoplasms, Anastrozole, Fulvestrant / pharmacokinetics, 03 medical and health sciences, breast cancer, Drug Therapy, Double-Blind Method, Diarrhea / epidemiology, Humans, Letrozole / pharmacokinetics, cyclin-dependent kinase inhibitor, Diarrhea / chemically induced, Original Articles, Breast Neoplasms / genetics, Aromatase Inhibitors / pharmacokinetics, Benzimidazoles
Zugangs-URL: https://onlinelibrary.wiley.com/doi/pdfdirect/10.1111/cas.14877
https://pubmed.ncbi.nlm.nih.gov/33686753
https://mayoclinic.pure.elsevier.com/en/publications/abemaciclib-in-combination-with-endocrine-therapy-for-east-asian-
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8177785/
https://onlinelibrary.wiley.com/doi/10.1111/cas.14877
https://snucm.elsevierpure.com/en/publications/abemaciclib-in-combination-with-endocrine-therapy-for-east-asian-
https://europepmc.org/article/MED/33686753
https://pubmed.ncbi.nlm.nih.gov/33686753/ -
5
Autoren: et al.
Weitere Verfasser: et al.
Quelle: Nature. 583:620-624
Schlagwörter: Leptin, Biological Factors/blood, Fulvestrant/administration & dosage, Fasting-mimicking diet, hormone therapy, breast cancer regression, Animals, Biological Factors, Breast Neoplasms, Diet Therapy, Diet, Healthy, Disease Models, Animal, Disease Progression, Drug Resistance, Neoplasm, Early Growth Response Protein 1, Fasting, Female, Fulvestrant, Humans, Insulin, Insulin-Like Growth Factor I, MCF-7 Cells, Mice, Inbred NOD, Mice, SCID, PTEN Phosphohydrolase, Piperazines, Pyridines, Receptors, Estrogen, Receptors, Progesterone, Tamoxifen, Xenograft Model Antitumor Assays, Drug Resistance, Drug Resistance, Neoplasm/drug effects, Mice, Neoplasm/drug effects, Receptors, Pyridines/administration & dosage, Progesterone, Research Support, Non-U.S. Gov't, Healthy/methods, 3. Good health, Insulin-Like Growth Factor I/metabolism, Diet Therapy/methods, Early Growth Response Protein 1/metabolism, PTEN Phosphohydrolase/metabolism, Tamoxifen/adverse effects, SCID, Fasting/physiology, Research Support, N.I.H., Extramural, Journal Article, Animal, Piperazines/administration & dosage, Estrogen, Diet, Leptin/blood, Disease Models, Breast Neoplasms/diet therapy, Inbred NOD, Insulin/blood, Diet, Healthy/methods, Research Support, U.S. Gov't, Non-P.H.S
Dateibeschreibung: application/pdf
Zugangs-URL: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7881940
https://pubmed.ncbi.nlm.nih.gov/32669709
https://hdl.handle.net/20.500.11755/72cead5c-ea9d-4dc1-99c2-446dc673ede1
https://doi.org/10.1038/s41586-020-2502-7
https://pure.knaw.nl/portal/en/publications/72cead5c-ea9d-4dc1-99c2-446dc673ede1
http://ui.adsabs.harvard.edu/abs/2020Natur.583..620C/abstract
https://econpapers.repec.org/RePEc:nat:nature:v:583:y:2020:i:7817:d:10.1038_s41586-020-2502-7
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC7881940/
http://www-nature-com-443.webvpn.bjmu.tsg211.com/articles/s41586-020-2502-7
https://pubmed.ncbi.nlm.nih.gov/32669709/
https://europepmc.org/article/MED/32669709
https://dspace.library.uu.nl/handle/1874/441128
https://hdl.handle.net/2434/1116432
https://doi.org/10.1038/s41586-020-2502-7
https://hdl.handle.net/11572/285312
https://doi.org/10.1038/s41586-020-2502-7
https://www.nature.com/articles/s41586-020-2502-7 -
6
Autoren: et al.
Weitere Verfasser: et al.
Quelle: Oncogene
Schlagwörter: 0301 basic medicine, Fulvestrant/administration & dosage, Pyridines, Nude, Drug Resistance, Drug Resistance, Neoplasm/drug effects, Cyclin-Dependent Kinase 4/genetics, Retinoblastoma Protein, Piperazines, Tamoxifen/administration & dosage, Mice, Neoplasm/drug effects, Receptors, Antineoplastic Combined Chemotherapy Protocols, Piperazines/pharmacology, Fulvestrant, Inbred BALB C, Pyridines/pharmacology, Mice, Inbred BALB C, 0303 health sciences, Tumor, Cyclin-Dependent Kinase 6/genetics, Receptors, Estrogen/genetics, 3. Good health, Receptors, Estrogen, MCF-7 Cells, Female, RNA Interference, Mice, Nude, Breast Neoplasms, Breast Neoplasms/genetics, Antineoplastic Combined Chemotherapy Protocols/pharmacology, Article, Cell Line, 03 medical and health sciences, SDG 3 - Good Health and Well-being, Cell Line, Tumor, Animals, Humans, Protein Kinase Inhibitors, Retinoblastoma Protein/genetics, Cyclin-Dependent Kinase 4, Estrogen/genetics, Cyclin-Dependent Kinase 6, Estrogen, Xenograft Model Antitumor Assays, Tamoxifen, Xenograft Model Antitumor Assays/methods, Drug Resistance, Neoplasm, Protein Kinase Inhibitors/pharmacology, Neoplasm
Dateibeschreibung: application/pdf; Print-Electronic
Zugangs-URL: https://www.nature.com/articles/s41388-020-1284-6.pdf
https://pubmed.ncbi.nlm.nih.gov/32307447
https://research-portal.uu.nl/en/publications/442e05a0-711a-4cd3-8f62-f3d965aa17b0
https://doi.org/10.1038/s41388-020-1284-6
https://www.nature.com/articles/s41388-020-1284-6.pdf
https://www.ncbi.nlm.nih.gov/pubmed/32307447
https://repository.icr.ac.uk/handle/internal/3597
https://europepmc.org/article/MED/32307447
https://www.nature.com/articles/s41388-020-1284-6
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7299844
https://dspace.library.uu.nl/handle/1874/410287 -
7
Autoren: et al.
Quelle: Lancet Oncol
Jones, R, Casbard, A, Carucci, M, Cox, C, Butler, R, Alchami, F, Madden, T-A, Bale, C, Bezecny, P, Joffe, J, Moon, S, Twelves, C, Venkitaraman, R, Waters, S, Foxley, A & Howell, S 2020, 'Fulvestrant plus capivasertib versus placebo after relapse or progression on an aromatase inhibitor in metastatic, oestrogen receptor-positive breast cancer (FAKTION) : a multicentre, randomised, controlled, phase 2 trial', The Lancet Oncology, vol. 21, no. 3, pp. 345-357. https://doi.org/10.1016/S1470-2045(19)30817-4Schlagwörter: 0301 basic medicine, Fulvestrant/administration & dosage, Drug Resistance, Drug Resistance, Neoplasm/drug effects, Breast/drug therapy, Neoplasm/drug effects, Ductal, Receptors, Antineoplastic Combined Chemotherapy Protocols, 80 and over, Neoplasm Metastasis, Fulvestrant, Aged, 80 and over, 0303 health sciences, Manchester Cancer Research Centre, Aromatase Inhibitors, Carcinoma, Ductal, Breast, Middle Aged, Prognosis, 3. Good health, Survival Rate, Neoplasm Recurrence, Local/drug therapy, Female, Receptors, Estrogen/metabolism, Adult, Breast Neoplasms, Carcinoma, Lobular/drug therapy, Article, Local/drug therapy, 03 medical and health sciences, Breast Neoplasms/drug therapy, Double-Blind Method, Lobular/drug therapy, Humans, Neoplasm Invasiveness, Pyrimidines/administration & dosage, Aged, Salvage Therapy, Aromatase Inhibitors/pharmacology, Pyrroles/administration & dosage, Carcinoma, ResearchInstitutes_Networks_Beacons/mcrc, name=Manchester Cancer Research Centre, Carcinoma, Lobular, Neoplasm Recurrence, Pyrimidines, Carcinoma, Ductal, Breast/drug therapy, Drug Resistance, Neoplasm, Antineoplastic Combined Chemotherapy Protocols/therapeutic use, Estrogen/metabolism, Neoplasm Recurrence, Local, Follow-Up Studies
Zugangs-URL: http://www.thelancet.com/article/S1470204519308174/pdf
https://pubmed.ncbi.nlm.nih.gov/32035020
https://orca.cardiff.ac.uk/id/eprint/129669/1/1-s2.0-S1470204519308174-main.pdf
https://research.manchester.ac.uk/en/publications/b253c20e-1d0d-4475-a468-3784a1027b23
https://doi.org/10.1016/S1470-2045(19)30817-4
https://www.research.manchester.ac.uk/portal/en/publications/fulvestrant -plus-capivasertib-azd5363-versus-placebo-after-relapse-or-progression-on-an-aromatase-inhibitor-in-metastatic-estrogen-receptor-positive-breast-cancer-faktion-a-multicentre-phase-2-randomised-controlled-trial(b253c20e-1d0d-4475-a468-3784a1027b23).html
https://www.sciencedirect.com/science/article/abs/pii/S1470204519308174
https://orca.cardiff.ac.uk/129669/
https://pubmed.ncbi.nlm.nih.gov/32035020/
https://www.sciencedirect.com/science/article/pii/S1470204519308174
https://www.thelancet.com/journals/lanonc/article/PIIS1470-2045(19)30817-4/fulltext -
8
Autoren: et al.
Quelle: RISalud-ANDALUCIA. Repositorio Institucional de Salud de Andalucía
instnameSchlagwörter: Receptor, ErbB-2, Oncologie, Aminopyridines, Kaplan-Meier Estimate, Breast Neoplasms/drug therapy/mortality, Aged, Antineoplastic Combined Chemotherapy Protocols, Breast Neoplasms, Drug Administration Schedule, Female, Fulvestrant, Humans, Middle Aged, Postmenopause, Progression-Free Survival, Purines, Receptors, Estrogen, Receptors, Progesterone, ErbB-2, 0302 clinical medicine, Receptors, PARTICIPANTS, Human health sciences, SCREENING TRIAL, POPULATION, 11 Medical and Health Sciences, Progesterone, Fulvestrant/administration & dosage/adverse effects, 3. Good health, PROBABILITY, Oncology, oncology, Life Sciences & Biomedicine, CT, Receptor, Receptor, erbB-2, DEATH VERIFICATION, Antineoplastic Combined Chemotherapy Protocols/adverse effects/therapeutic use, Aminopyridines/administration & dosage/adverse effects, Sciences de la santé humaine, 03 medical and health sciences, Medicine, General & Internal, NODULES, General & Internal Medicine, MANAGEMENT, Purines/administration & dosage/adverse effects, Science & Technology, 42 Health sciences, MORTALITY, 32 Biomedical and clinical sciences, Estrogen, LUNG
Zugangs-URL: https://pubmed.ncbi.nlm.nih.gov/31826360
http://hdl.handle.net/10668/14815
http://hdl.handle.net/11588/804127
https://www.ncbi.nlm.nih.gov/pubmed/31826360
https://europepmc.org/article/MED/31826360
https://www.nejm.org/doi/full/10.1056/NEJMoa1911149
https://moh-it.pure.elsevier.com/en/publications/overall-survival-with-ribociclib-plus-fulvestrant -in-advanced-bre-3
https://snucm.elsevierpure.com/en/publications/overall-survival-with-ribociclib-plus-fulvestrant -in-advanced-bre
https://www.nejm.org/doi/pdf/10.1056/NEJMoa1911149?articleTools=true
https://lirias.kuleuven.be/handle/123456789/646270
https://doi.org/10.1056/nejmoa1911149
https://hdl.handle.net/2268/245119
https://doi.org/10.1056/NEJMoa1911149
https://hdl.handle.net/10668/14815 -
9
Autoren: et al.
Quelle: Alves, C L, Ehmsen, S, Terp, M G, Portman, N, Tuttolomondo, M, Gammelgaard, O L, Hundebøl, M F, Kaminska, K, Johansen, L E, Bak, M, Honeth, G, Bosch, A, Lim, E & Ditzel, H J 2021, 'Co-targeting CDK4/6 and AKT with endocrine therapy prevents progression in CDK4/6 inhibitor and endocrine therapy-resistant breast cancer', Nature Communications, vol. 12, 5112. https://doi.org/10.1038/s41467-021-25422-9
Schlagwörter: Breast Neoplasms/drug therapy, Cell Line, Tumor, Cyclin-Dependent Kinase 4/antagonists & inhibitors, Cyclin-Dependent Kinase 6/antagonists & inhibitors, Disease Progression, Drug Resistance, Neoplasm, Drug Therapy, Combination, Female, Fulvestrant/administration & dosage, Humans, Molecular Targeted Therapy, Protein Kinase Inhibitors/administration & dosage, Proto-Oncogene Proteins c-akt/genetics
-
10
Autoren: et al.
Weitere Verfasser: et al.
Schlagwörter: Animals, Antineoplastic Combined Chemotherapy Protocols/pharmacology, Breast Neoplasms/genetics, Cell Line, Tumor, Cyclin-Dependent Kinase 4/genetics, Cyclin-Dependent Kinase 6/genetics, Drug Resistance, Neoplasm/drug effects, Female, Fulvestrant/administration & dosage, Humans, MCF-7 Cells, Mice, Inbred BALB C, Nude, Piperazines/pharmacology, Protein Kinase Inhibitors/pharmacology, Pyridines/pharmacology, RNA Interference, Receptors, Estrogen/genetics, Retinoblastoma Protein/genetics, Tamoxifen/administration & dosage, Xenograft Model Antitumor Assays/methods
Dateibeschreibung: application/pdf
Verfügbarkeit: https://dspace.library.uu.nl/handle/1874/410287
-
11
Autoren: et al.
Quelle: Alves, C M L, Elias, D, Lyng, M B, Bak, M & Ditzel, H 2018, 'SNAI2 upregulation is associated with an aggressive phenotype in fulvestrant-resistant breast cancer cells and is an indicator of poor response to endocrine therapy in estrogen receptor-positive metastatic breast cancer', Breast Cancer Research, vol. 20, 60. https://doi.org/10.1186/s13058-018-0988-9
Schlagwörter: Endocrine resistance, Epithelial-mesenchymal transition, Estrogen receptor-positive breast cancer, Fulvestrant, SNAI2, Antineoplastic Agents, Hormonal/administration & dosage, Fulvestrant/administration & dosage, Humans, Middle Aged, Snail Family Transcription Factors/genetics, Neoplasm Metastasis, Estrogen Receptor alpha/genetics, MCF-7 Cells, Drug Resistance, Neoplasm/genetics, Epithelial-Mesenchymal Transition/drug effects, Adult, Female, Aged, Cell Proliferation/drug effects, Gene Expression Regulation, Neoplastic/genetics, Breast Neoplasms/drug therapy
Dateibeschreibung: application/pdf
-
12
Autoren: et al.
Weitere Verfasser: et al.
Schlagwörter: Animals, Biological Factors/blood, Breast Neoplasms/diet therapy, Diet Therapy/methods, Diet, Healthy/methods, Disease Models, Animal, Disease Progression, Drug Resistance, Neoplasm/drug effects, Early Growth Response Protein 1/metabolism, Fasting/physiology, Female, Fulvestrant/administration & dosage, Humans, Insulin-Like Growth Factor I/metabolism, Insulin/blood, Leptin/blood, MCF-7 Cells, Mice, Inbred NOD, SCID, PTEN Phosphohydrolase/metabolism, Piperazines/administration & dosage, Pyridines/administration & dosage, Receptors, Estrogen, Progesterone, Tamoxifen/adverse effects
Dateibeschreibung: application/pdf
Verfügbarkeit: https://dspace.library.uu.nl/handle/1874/441128
Full Text 
Full Text Finder 
Nájsť tento článok vo Web of Science